Taken together, our data identify H1‐0 as a key regulator of the ETV6::RUNX1+ transcriptome and indicate that the addition of Quisinostat may be beneficial to target non‐responsive or relapsing ETV6::RUNX1+ BCP‐ALL. This evidence concerns the gene ETV6 and acute lymphoblastic leukemia.